{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:24:11Z","timestamp":1793665451465,"version":"4.5.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.coph.2025.102526","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:12:25Z","timestamp":1744132345000},"page":"102526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction"],"prefix":"10.1016","volume":"82","author":[{"given":"Bofei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick K.","family":"Reville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein A.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2025.102526_bib1","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: new drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.coph.2025.102526_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-024-01033-7","article-title":"Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century","volume":"14","author":"Hemminki","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.coph.2025.102526_bib3","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2018016378","article-title":"Evaluating measurable residual disease in acute myeloid leukemia","volume":"2","author":"Ravandi","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2025.102526_bib4","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMc1805501","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Mauvieux","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102526_bib5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102526_bib6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2025.102526_bib7","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1182\/blood-2011-06-364182","article-title":"A clinically relevant population of leukemic CD34+CD38\u2212 cells in acute myeloid leukemia","volume":"119","author":"Gerber","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102526_bib8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.stem.2019.07.001","article-title":"Interconversion between tumorigenic and differentiated states in acute myeloid leukemia","volume":"25","author":"McKenzie","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.coph.2025.102526_bib9","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 eradicates human acute myeloid leukemic stem cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2025.102526_bib10","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1073\/pnas.0704271104","article-title":"CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia","volume":"104","author":"Hosen","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.coph.2025.102526_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal antibody-mediated targeting of CD123, IL-3 receptor \u03b1 chain, eliminates human acute myeloid leukemic stem cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.coph.2025.102526_bib12","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood.2023021680","article-title":"CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia","volume":"144","author":"Mazziotta","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102526_sref13","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159579","article-title":"Immune dysfunction signatures predict outcomes and define checkpoint blockade\u2013unresponsive microenvironments in acute myeloid leukemia","volume":"132","author":"Rutella","year":"2022","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coph.2025.102526_bib14","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/2326-6066.CIR-22-0961","article-title":"Single-cell profiling of CD8+ T cells in acute myeloid leukemia reveals a continuous spectrum of differentiation and clonal hyperexpansion","volume":"11","author":"Desai","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.coph.2025.102526_bib15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102526_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.20.00475","article-title":"Immune biology of acute myeloid leukemia: implications for immunotherapy","volume":"39","author":"Khaldoyanidi","year":"2021","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.coph.2025.102526_bib17","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1038\/s41467-023-38113-4","article-title":"Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation","volume":"14","author":"Pagliuca","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2025.102526_bib18","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","article-title":"Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2025.102526_sref19","first-page":"27","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry","year":"2023","journal-title":"Nat Can (Ott)"},{"key":"10.1016\/j.coph.2025.102526_bib20","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/2159-8290.CD-21-1146","article-title":"The impact of inflammation-induced tumor plasticity during myeloid transformation","volume":"12","author":"Yeaton","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.coph.2025.102526_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102526_bib22","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/ni1080","article-title":"Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity","volume":"5","author":"Hope","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coph.2025.102526_bib23","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1101\/gad.1143403","article-title":"Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors","volume":"17","author":"Cozzio","year":"2003","journal-title":"Genes Dev"},{"key":"10.1016\/j.coph.2025.102526_bib24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","article-title":"Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia","volume":"19","author":"Goardon","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coph.2025.102526_bib25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI41495","article-title":"Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD\/SCID\/IL2R\u03b3c-deficient mice","volume":"121","author":"Sarry","year":"2011","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coph.2025.102526_bib26","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1084\/jem.20151775","article-title":"Genetically distinct leukemic stem cells in human CD34\u2212 acute myeloid leukemia are arrested at a hemopoietic precursor-like stage","volume":"213","author":"Quek","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2025.102526_sref27","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"Galen van","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.coph.2025.102526_sref28","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2025.102526_bib29","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s42003-023-05120-6","article-title":"Single-cell chromatin accessibility profiling of acute myeloid leukemia reveals heterogeneous lineage composition upon therapy-resistance","volume":"6","author":"Fan","year":"2023","journal-title":"Commun Biol"},{"key":"10.1016\/j.coph.2025.102526_sref30","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","article-title":"A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy","volume":"13","author":"Pei","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.coph.2025.102526_sref31","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.coph.2025.102526_sref32","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.stem.2023.04.001","article-title":"Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia","volume":"30","author":"Beneyto-Calabuig","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.coph.2025.102526_bib33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ccr.2008.03.005","article-title":"Malignant transformation initiated by mll-AF9: gene dosage and critical target cells","volume":"13","author":"Chen","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coph.2025.102526_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103710","article-title":"Leukemic stem cells as a target for eliminating acute myeloid leukemia: gaps in translational research","volume":"175","author":"Khaldoyanidi","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.coph.2025.102526_bib35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3390\/cancers13030469","article-title":"The CXCL12 crossroads in cancer stem cells and their niche","volume":"13","author":"L\u00f3pez-Gil","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.coph.2025.102526_bib36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature10783","article-title":"Endothelial and perivascular cells maintain haematopoietic stem cells","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102526_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.896426","article-title":"Drug resistance mechanisms of acute myeloid leukemia stem cells","volume":"12","author":"Niu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.coph.2025.102526_bib38","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14728222.2022.2083957","article-title":"Acute myeloid leukemia: therapeutic targeting of stem cells","volume":"26","author":"Pabon","year":"2022","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.coph.2025.102526_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.632789","article-title":"Harnessing the metabolic vulnerabilities of leukemia stem cells to eradicate acute myeloid leukemia","volume":"11","author":"Kumar","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.coph.2025.102526_sref40","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coph.2025.102526_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-CAR T cells induce remissions in CD19-CAR na\u00efve and resistant B-all","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2025.102526_bib42","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102526_bib43","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102526_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2025","article-title":"CD99 is a therapeutic target on disease stem cells in myeloid malignancies","volume":"9","author":"Chung","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2025.102526_bib45","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/stem.2897","article-title":"c-MPL is a candidate surface marker and confers self-renewal, quiescence, chemotherapy resistance, and leukemia initiation potential in leukemia stem cells","volume":"36","author":"Li","year":"2018","journal-title":"Stem Cell"},{"key":"10.1016\/j.coph.2025.102526_bib46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-019-0522-9","article-title":"Targeting cell membrane HDM2: a novel therapeutic approach for acute myeloid leukemia","volume":"34","author":"Wang","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102526_bib47","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7076","article-title":"A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure","volume":"41","author":"Short","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102526_bib48","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.coph.2025.102526_bib49","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II trial of pembrolizumab after high dose cytarabine in relapsed\/refractory acute myeloid leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.coph.2025.102526_bib50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood-2023-187307","article-title":"Single-cell characterization of TP53-mutated AML patients treated with frontline azacitidine, venetoclax, and magrolimab reveals mechanisms of response and resistance","volume":"142","author":"Desai","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102526_bib51","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.2022018246","article-title":"Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease","volume":"141","author":"Penter","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102526_bib52","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1038\/s41467-021-26282-z","article-title":"Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy","volume":"12","author":"Abbas","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2025.102526_bib53","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1200\/JCO.19.01823","article-title":"Integrating the \u201cimmunome\u201d in the stratification of myelodysplastic syndromes and future clinical trial design","volume":"38","author":"Winter","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102526_bib54","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coph.2025.102526_bib55","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/2767-9764.CRC-23-0402","article-title":"Single-cell CD4 and CD8 T-cell secretome profiling reveals temporal and niche differences in acute myeloid leukemia following immune checkpoint blockade therapy","volume":"4","author":"Root","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.coph.2025.102526_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2025.102526_sref57","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1158\/2159-8290.CD-21-0956","article-title":"Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts","volume":"12","author":"Ellegast","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.coph.2025.102526_bib58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.coph.2025.102526_bib59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/978-3-030-79308-1_9","article-title":"An update on immune based therapies in acute myeloid leukemia: 2021 and beyond","volume":"1342","author":"Haddad","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.coph.2025.102526_bib60","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102526_bib61","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2025.102526_bib62","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood.2024024000","article-title":"IL-9 secreted by leukemia stem cells induces Th1-skewed CD4+ T cells, which promote their expansion","volume":"144","author":"Radpour","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102526_bib63","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-21-3594","article-title":"Release of IFN\u03b3 by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells","volume":"28","author":"Corradi","year":"2022","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.coph.2025.102526_bib64","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.3390\/cells10123376","article-title":"The role of T cell immunotherapy in acute myeloid leukemia","volume":"10","author":"Hao","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.coph.2025.102526_bib65","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3390\/cancers13061423","article-title":"Redirecting the immune microenvironment in acute myeloid leukemia","volume":"13","author":"Sendker","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.coph.2025.102526_bib66","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.coph.2025.102526_bib67","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3390\/ijms18102129","article-title":"Control of NK cell activation by immune checkpoint molecules","volume":"18","author":"Beldi-Ferchiou","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2025.102526_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp0004","article-title":"BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML","volume":"16","author":"Kumar","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2025.102526_bib69","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coph.2025.102526_bib70","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-020-00996-x","article-title":"Natural killer cell-based immunotherapy for acute myeloid leukemia","volume":"13","author":"Xu","year":"2020","journal-title":"J Hematol Oncol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:18:14Z","timestamp":1762546694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489225000220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":70,"alternative-id":["S1471489225000220"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2025.102526","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2025.102526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102526"}}